LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-11. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
==== Antihormonal activity ==== As an antiandrogen, ketoconazole operates through at least two mechanisms of action. First, and most notably, high oral doses of ketoconazole (e.g. 400 mg three times per day) block both testicular and adrenal androgen biosynthesis, leading to a reduction in circulating testosterone levels. It produces this effect through inhibition of 17α-hydroxylase and 17,20-lyase, which are involved in the synthesis and degradation of steroids, including the precursors of testosterone. Due to its efficacy at reducing systemic androgen levels, ketoconazole has been used with some success as a treatment for androgen-dependent prostate cancer. Second, ketoconazole is an androgen receptor antagonist, competing with androgens such as testosterone and dihydrotestosterone (DHT) for binding to the androgen receptor. This effect is thought to be quite weak however, even with high oral doses of ketoconazole. Ketoconazole, along with miconazole, has been found to act as an antagonist of the glucocorticoid receptor. Ketoconazole is a racemic mixture consisting of cis-(2S,4R)-(−) and cis-(2R,4S)-(+) enantiomers. The cis-(2S,4R) isomer was more potent in inhibiting progesterone 17α,20-lyase than its enantiomer (IC50 values of 0.05 and 2.38 μM, respectively) and in inhibiting 11β-hydroxylase (IC50 values of 0.152 and 0.608 μM, respectively). Both isomers were relatively weak inhibitors of human placental aromatase. Oral ketoconazole has been used clinically as a steroidogenesis inhibitor in men, women, and children at dosages of 200 to 1,200 mg/day.
=== 20th century === From the first half of the twentieth century, physicians used other substances as breast implant fillers—ivory, glass balls, ground rubber, ox cartilage, Terylene wool, gutta-percha, Dicora, polyethylene chips, Ivalon (polyvinyl alcohol—formaldehyde polymer sponge), a polyethylene sac with Ivalon, polyether foam sponge (Etheron), polyethylene tape (Polystan) strips wound into a ball, polyester (polyurethane foam sponge) Silastic rubber, and teflon-silicone prostheses. In the mid-twentieth century, Morton I. Berson, in 1945, and Jacques Maliniac, in 1950, each performed flap-based breast augmentations by rotating the patient's chest wall tissue into the breast to increase its volume. Furthermore, throughout the 1950s and the 1960s, plastic surgeons used synthetic fillers—including silicone injections received by some 50,000 women, from which developed silicone granulomas and breast hardening that required treatment by mastectomy. In 1961, the American plastic surgeons Thomas Cronin and Frank Gerow, and the Dow Corning Corporation, developed the first silicone breast prosthesis, filled with silicone gel; in due course, the first augmentation mammoplasty was performed in 1962 using the Cronin–Gerow Implant, prosthesis model 1963. In 1964, the French company Laboratoires Arion developed and manufactured the saline breast implant, filled with saline solution, and then introduced for use as a medical device in 1964.
== Cancelled spin-off == After the series' cancellation, it was revealed that a spin-off revolving around Infinity Inc. was planned and that it would have followed the Shade, Jennie, and Todd searching for the other offspring of the original JSA members and help them with their potential abilities.
Sources: en.wikipedia.org
Systematic doping in Russian sports has resulted in 47 Olympic and tens of world championships medals being stripped from Russian competitors—the most of any country, more than four times the number of the runner-up, and more than 30% of the global total. Russia also has the most competitors that have been caught doping at the Olympic Games, with more than 200. Russian doping is distinct from doping in other countries because in Russia the state supplied steroids and other drugs to sportspeople. Due to widespread doping violations, including an attempt to sabotage ongoing investigations by the manipulation of computer data, on 9 December 2019 the World Anti-Doping Agency (WADA) banned Russia from all international sport for four years. As at the 2018 Winter Olympics, WADA will allow individual cleared Russian athletes to compete neutrally under a title to be determined (which may not include the name "Russia", unlike the use of "Olympic Athletes from Russia" in 2018). Russia later filed an appeal to the Court of Arbitration for Sport (CAS) against the WADA decision. The Court of Arbitration for Sport, on review of Russia's appeal of its case from WADA, ruled on 17 December 2020 to reduce the penalty that WADA had imposed. Instead of banning Russia from sporting events, the ruling allowed Russia to participate at the Olympics and other international events, but for a period of two years the team cannot use the Russian name, flag, or anthem and must present themselves as "Neutral Athlete" or "Neutral Team".
=== Multiple risk factor theory === Another theory is that there may be shared risk factors that can lead to both substance use and mental illness. Mueser hypothesizes that these may include factors such as social isolation, poverty, lack of structured daily activity, lack of adult role responsibility, living in areas with high drug availability, and association with people who already misuse drugs. Other evidence suggests that traumatic life events, such as sexual abuse, are associated with the development of psychiatric problems and substance use.
Early medical texts, especially the Carakasaṃhitā and Suśrutasaṃhitā, are often claimed to contain early references to rasaśāstra. Where these texts use the word rasa, later commentators interpret rasa as mercury, despite the word having various other meanings. The earliest mentions of mercury are to the unprocessed substance and it is not until the 9th century Kalyāṇakāraka that we find recipes for purifying and calcination. The 13th century Śārṅgadharasaṃhitā also contains elaborate descriptions of the processing and uses of mercury. An important feature is the use of metals, including several that are toxic. In addition to mercury, gold, silver, iron, copper, tin, lead, zinc and bell metal are used. In addition to these metals, salts and other substances such as coral, seashells, and feathers are also used. The usual means used to administer these substances is by preparations called bhasma, Sanskrit for "ash". Calcination, which is described in the literature of the art as śodhana, "purification", is the process used to prepare these bhasma for administration. Sublimation and the preparation of a mercury sulfide are also in use in the preparation of its materia medica. A variety of methods are used to achieve this. One involves the heating of thin sheets of metal and then immersing them in oil (taila), extract (takra), cow urine (gomutra) and other substances. Others are calcined in crucibles heated with fires of cow dung (puttam). Ayurvedic practitioners believe that this process of purification removes undesirable qualities and enhances their therapeutic power.
Sources: en.wikipedia.org
== Medical uses == In the United States, daptomycin is indicated for use in adults for skin and skin structure infections caused by Gram-positive infections, S. aureus bacteremia, and right-sided S. aureus endocarditis. In 2017, the FDA extended daptomycin's indications to pediatric patients aged 1 to 17 years: labeling for complicated skin and skin structure infections in this population was approved on 29 March 2017, and labeling for S. aureus bacteremia in pediatric patients was approved on 1 September 2017. Daptomycin is not recommended for patients younger than one year of age, given the potential for adverse effects on the muscular, neuromuscular, and nervous systems observed in neonatal animal studies. It binds avidly to pulmonary surfactant, and so is generally ineffective in treating pneumonia.
=== Branch-chain fatty acid synthase === This system functions similarly to the branch-chain fatty acid synthesizing system, however it uses short-chain carboxylic acids as primers instead of alpha-keto acids. In general, this method is used by bacteria that do not have the ability to perform the branch-chain fatty acid system using alpha-keto primers. Typical short-chain primers include isovalerate, isobutyrate, and 2-methyl butyrate. In general, the acids needed for these primers are taken up from the environment; this is often seen in ruminal bacteria. The overall reaction is:
Controversy soon arose over the size of UNTAG's military component, as the member states of the Security Council expected to cover the majority of the costs were irritated by its relatively large size. However, Angola, Zambia, and other states sympathetic to PLAN insisted that a larger force was necessary to ensure that South Africa did not interfere with independence proceedings. Against their objections UNTAG's force levels were reduced from the proposed 7,500 to three battalions of 4,650 troops. This slashed projected expenses by nearly 300 million dollars, but the Security Council did not approve the revised budget until 1 March 1989. The inevitable delay in UNTAG's full deployment ensured there were insufficient personnel prepared to monitor the movement of PLAN and the SADF or their confinement to bases on 1 April 1989, when the permanent cessation in hostilities was to take effect. Secretary-General de Cuéllar urged restraint in the interim on both sides to avoid jeopardising the de facto ceasefire maintained since August 1988 or the 1 April implementation schedule. Nevertheless, PLAN took advantage of the political uncertainty in the weeks following the UNTAG budget debate to begin moving its forces in Angola closer to the border. Since the early 1980s PLAN had consistently stated its intention to establish camps inside South West Africa during any future political transition, a notion rejected with equal consistency by the South African government.
Pasteur effect Also Pasteur-Meyerhof effect. A phenomenon observed in facultatively anaerobic cells, including animal tissues and many microorganisms such as yeast, whereby the presence of oxygen in the environment inhibits the cell's use of ethanol fermentation pathways to generate energy, and drives the cell to instead make use of the available oxygen in aerobic respiration; or more generally the observed decrease in the rate of glycolysis or of lactate production in cells exposed to oxygenated air.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.